Durham startup targeting pancreatitis raises $2.7M from 19 investors

On May 5, 2020 Lamassu Pharma, a biotech startup that is developing small molecule therapeutics to treat acute pancreatitis, reported the company has found plenty of investors despite the ongoing COVID-19 pandemic (Press release, Lamassu Pharma, MAY 5, 2020, View Source [SID1234646264]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Durham firm says in an SEC filing that it has raised nearly $2.7 million.

And 19 investors are backing the company with a minimum investment of $50,000.

Lamassu is looking to raise another $200,000 in a round of equity with a near-$3 million target.

"We capitalizing on our expertise in early translational research to bring products to phase I/II, then partner with clinical and commercial development specialists. Our innovative model ensures that early development efforts bring product to definitive clinical testing as efficiently as possible to benefit patients and ensure early investment will lead to clinical results," the company says.

"Our lead candidate is a novel small molecule therapy for acute pancreatitis. This was developed at Mayo Clinic by leading scientists, and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. We are currently focused on continued development of this compound through safety testing in preparation for definitive clinical trials. Our ultimate goal is saving the lives of patients afflicted with this disease."

Lamassu launched in 2018.

Founders include:

GABI HANNA, MD, CEO and Co-Founder
Physician, and co-founder of Lamassu Pharma. Research focus on translational medicine and commercialization, bringing innovations to clinical trial and patient benefit.

GREG PALMER, PHD, CSO and Co-Founder
Biomedical engineer with expertise in imaging, medical devices, and translational science.

RABI HANNA, MD, CMO and Co-Founder
Chair of Pediatric Oncology at Cleveland Clinical, brings translational and clinical expertise.

PRESS RELEASE – CLINICAL TRIAL COLLABORATION AGREEMENT WITH MSD (MERCK US)

On May 5, 2020 NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company developing therapeutics based on dependence receptor biology, reported that it has entered into a clinical collaboration agreement with MSD to investigate the safety, clinical and biological activity of NP137 with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with locally advanced/metastatic uterine tumors. NP137 targets netrin-1, which is overexpressed in over two-thirds of uterine tumors (Press release, Netris Pharma, MAY 5, 2020, View Source [SID1234611183]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The companies have entered this collaboration based on promising clinical data obtained from a phase 1 trial investigating NP137 monotherapy in patients with advanced solid tumors and the growing evidence that resistance to an anti-PD-1 therapy, such as KEYTRUDA, can be alleviated when combined with blocking netrin-1.

Under the terms of the agreement, NETRIS will sponsor a large phase 1b/2 study, which will be conducted in collaboration with the Centre Léon Bérard and with support of the specialist French oncology group of clinicians, GINECO (Groupe d’Investigateurs National des Etudes des Cancers Ovariens). The study will investigate the safety and efficacy of NP137 combined with KEYTRUDA in patients with advanced/metastatic endometrial carcinoma or cervix carcinoma.

"We are excited to collaborate with MSD, an established leader in cancer immunotherapy, on our proof-of-concept phase1b/2 study as we work to improve the lives of cancer patients," said Patrick Mehlen, Founder and Chief Executive Officer of NETRIS Pharma. "Immunotherapies are revolutionizing the treatment of patients in several cancer indications, but there remain many other tumor types in which existing immunotherapies have not demonstrated sufficient efficacy. Based on our preclinical and clinical data demonstrating the role of netrin-1 in promoting tumor progression and modulating tumor plasticity and microenvironment, we believe NP137’s effect in combination with KEYTRUDA will lead superior patient response to immunotherapy."

"The preliminary safety data and anti-tumor activity observed in the Phase 1a trial, together with the unique mode of action of NP137, are very exciting and clearly support evaluating a combination with KEYTRUDA," said Isabelle Ray Coquard, MD, Ph.D. and Principal Investigator of the trial. "We anticipate starting the study summer 2020."

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

The Phase 1b/2 clinical trial will enroll up to 240 patients and be divided into a Ph1b part to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of the NP137 KEYTRUDA combination and/or chemotherapeutic agents. The Phase 2 part will assess via randomization the clinical activity of the combination in both tumor types.

About NP137
NP137, a humanized monoclonal antibody of isotype IgG1 directed against netrin-1, is the first drug candidate developed by NETRIS Pharma. Most types of tumors produce an abnormal amount of dependence receptors’ ligands, which prevents cells from dying. Netrin-1 is overexpressed in a large percentage of human cancers, including over two thirds of gynecologic cancers.

In preclinical studies, NP137 inhibited tumor growth and had a significant impact on tumoral plasticity, which potentiates the efficacy of chemotherapies and immune checkpoint inhibitors. In the phase 1 dose-escalation study, NP137 was found to be safe and very well tolerated up to 20mg/kg, with no dose limiting toxicity (DLT). In addition, patients with advanced uterine cancers exhibited encouraging signs of anti-tumor activity, including prolonged stable disease and objective responses.

About GINECO
GINECO (Groupe d’Investigateurs National pour l’Etude des Cancers de l’Ovaire et du sein) is the French Cooperative Group in Oncology labelled by INCA (National Cancer Institute in France) developing and conducting gynecological and metastatic breast cancer clinical trials at the national and international level. The network comprises more than 700 specialized investigators representing more than 150 public or private oncology units.

MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

On May 5, 2020 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported financial results for the quarter ended March 31, 2020 (Press release, MacroGenics, MAY 5, 2020, View Source [SID1234557018]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the progress and clinical activity that we continue to observe across our broad portfolio of seven antibody-based product candidates, and we anticipate presenting clinical data from all these molecules this year. In the near-term, we look forward to sharing the initial data from our Phase 1 studies of MGD013 and MGC018 at ASCO (Free ASCO Whitepaper) and our plans for further development of these promising candidates," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "While we expect some near-term impact on clinical trial site initiation and patient enrollment due to the unprecedented challenges posed by the COVID-19 pandemic, we have not changed our guidance for the timing of anticipated 2020 clinical data read-outs or regulatory events."

Recent and Anticipated Presentation of Clinical Data

At the recent American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting I held April 27-28, an academic collaborator presented data during a plenary session suggesting that TP53 mutational status in patients with acute myeloid leukemia (AML) correlated with an immune-infiltrated tumor microenvironment that was associated with response to flotetuzumab, an investigational, bispecific CD123 x CD3 DART molecule.

At the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in May, MacroGenics plans to present the following clinical data:

An oral presentation covering dose escalation and select expansion cohorts from the ongoing Phase 1 study of MGD013, an investigational, bispecific PD-1 x LAG-3 DART molecule;

A poster presentation covering initial dose escalation data from the ongoing Phase 1/2 study of MGC018, an investigational antibody-drug conjugate targeting B7-H3; and

A poster presentation covering results stratified by chemotherapy from the Phase 3 SOPHIA study of chemotherapy plus margetuximab, an investigational, Fc-engineered, anti-HER2 monoclonal antibody, compared to chemotherapy plus trastuzumab in patients with HER2-positive metastatic breast cancer.

MacroGenics also anticipates the presentation of the following clinical data in the second half of 2020:

Final overall survival (OS) analysis for the Phase 3 SOPHIA study of margetuximab;

Initial data from the Phase 2/3 MAHOGANY study of margetuximab plus checkpoint blockade in patients with advanced gastric cancer;

Data from the Phase 1 dose escalation study of MGD019, an investigational, bispecific, PD-1 x CTLA-4 DART molecule;

Additional data on flotetuzumab in AML patients who are refractory to induction treatment (primary induction failure); and

Incyte expects to present data from its study of retifanlimab (formerly known as MGA012 or INCMGA0012) in patients with anal cancer, which is now fully enrolled, and is one of three ongoing potentially registration-enabling monotherapy studies. Retifanlimab is an investigational anti-PD-1 monoclonal antibody invented by MacroGenics and licensed to Incyte.
Regulatory Interactions and Events

MacroGenics anticipates a Prescription Drug User Fee Act (PDUFA) target action date in December 2020 for margetuximab in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer. The Food and Drug Administration (FDA) has indicated its plan to schedule an Oncologic Drugs Advisory Committee (ODAC) meeting in the second half of 2020.

MacroGenics will meet with the FDA this quarter to gain feedback on the planned registration path in the U.S. for flotetuzumab for the treatment of patients with AML who are refractory to induction treatment (primary induction failure).
Clinical Trial Updates and Status

In consideration of current global and domestic COVID-19 pandemic, the planned Phase 2 study initiation of enoblituzumab will be delayed. Enoblituzumab is an investigational, Fc-engineered, anti-B7-H3 monoclonal antibody which is being studied in combination with checkpoint blockade for the treatment of patients with advanced head and neck cancer. The Company expects to provide updates on the timing for initiating the study in the second half of 2020.

MacroGenics has stopped enrollment in an ex-U.S. Phase 1/2 study combining flotetuzumab with retifanlimab in patients with relapsed or refractory AML. The decision was not due to any safety finding or lack of activity, and the Company plans to resume the study in the U.S. in the future.

MacroGenics continues to open clinical sites globally to enroll patients in the Phase 2/3 MAHOGANY study evaluating the combination of margetuximab and retifanlimab as a front-line treatment for advanced gastric and gastroesophageal junction cancer. Zai Lab, MacroGenics’ regional partner in Greater China, has stated that it expects sites in its territory to enroll patients starting in the second half of 2020.

MacroGenics and Zai Lab, its regional partner in Greater China, are continuing to broadly explore the development of MGD013 across multiple indications. MGD013 is being studied both as a monotherapy and in combination with other pipeline assets. Zai Lab has initiated combination studies with niraparib, a PARP inhibitor, and brivanib, a dual target tyrosine kinase inhibitor of the VEGF and FGF receptors, for the study of advanced gastric cancer and hepatocellular carcinoma, respectively.
First Quarter 2020 Financial Results

Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2020, were $170.8 million, compared to $215.8 million as of December 31, 2019.

Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was $13.7 million for the quarter ended March 31, 2020, compared to $9.7 million for the quarter ended March 31, 2019. This increase was primarily due to revenue recognized for manufacturing services under the Clinical Supply Agreements with Incyte and Zai Lab, as well as milestone payments under the Zai Lab Agreement for clinical trial initiations in Greater China.

R&D Expenses: Research and development expenses were $48.9 million for the quarter ended March 31, 2020, compared to $47.1 million for the quarter ended March 31, 2019. This increase was primarily due to an increase in development and clinical trial costs for multiple programs.

G&A Expenses: General and administrative expenses were $10.2 million for the quarter ended March 31, 2020, compared to $10.2 million for the quarter ended March 31, 2019.

Net Loss: Net loss was $44.7 million for the quarter ended March 31, 2020, compared to net loss of $45.0 million for the quarter ended March 31, 2019.

Shares Outstanding: Shares outstanding as of March 31, 2020 were 49,131,150.

Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities as of March 31, 2020, combined with anticipated and potential collaboration payments, should enable it to fund its operations into 2022, assuming the Company’s programs and collaborations advance as currently contemplated.
Conference Call Information

MacroGenics will host a conference call today at 4:30 p.m. ET to discuss financial results for the quarter ended March 31, 2020 and provide a corporate update. To participate in the conference call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) ten minutes prior to the start of the call and provide the Conference ID: 2993147.

The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

Supernus Announces First Quarter 2020 Financial Results

On May 5, 2020 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported financial results for the first quarter of 2020 and associated Company developments (Press release, Supernus, MAY 5, 2020, View Source [SID1234557035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commercial Update

First quarter 2020 product prescriptions for Trokendi XR and Oxtellar XR, as reported by IQVIA, totaled 203,404, a 2% increase over first quarter 2019.

First quarter 2020 net product sales were $92.5 million, an increase of 11% over $83.1 million in the first quarter of 2019. As previously disclosed, wholesalers, distributors, and pharmacies decreased their inventory levels of the Company’s products in the first quarter of 2019. The Company estimates that this caused net product sales in the first quarter of 2019 to be approximately $10 million lower had inventory levels remained constant, thus favorably impacting year over year net product sales growth in the first quarter of 2020.

Supply of Trokendi XR and Oxtellar XR has not been impacted by COVID-19. The Company has adequate inventory on hand for both products to continue to be available to patients.

Corporate and Product Pipeline Update

SPN-812 – Novel non-stimulant for the treatment of ADHD

The Company continues to prepare for the commercial launch of SPN-812 at the end of 2020.
The Company remains engaged with the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for SPN-812 for the treatment of ADHD, which has a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020.
The Phase III program in adult patients reached approximately 75% of the targeted enrollment before additional enrollment was put on hold in March 2020 due to the impact of COVID-19. The Company is employing virtual efforts to ensure that currently enrolled subjects can progress to completion of treatment. This trial was ahead of schedule prior to the COVID-19 pandemic, with a potential data release in the second half of this year. Depending on when the Company can restart enrollment and complete the study, data from the trial may be pushed into 2021.
CNS portfolio of US WorldMeds

As announced last week, Supernus entered into a definitive Sale and Purchase Agreement to acquire the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company. The acquisition is expected to close in the second quarter of 2020, subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.
US WorldMeds’ CNS portfolio consists of three marketed products with 2019 net sales and operating earnings of approximately $150 million and $45 million, respectively, and a product candidate with an expected NDA submission in the second half of 2020.
The acquisition expands and strengthens the Company’s neurology portfolio, diversifies its revenue and operating cash flow base and enhances long term growth.
Total consideration consists of an upfront cash payment of $300 million plus regulatory and commercial milestone cash payments up to $230 million. All cash consideration will be funded through existing balance sheet cash.
SPN-820 (NV-5138) – novel first-in-class activator of mTORC1

Supernus and Navitor Pharmaceuticals, Inc., a privately-held company, announced a joint Development and Option Agreement for Navitor’s mTORC1 activator, NV-5138.
Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. Supernus will pay up to $50 million of the costs of Phase II development, plus certain costs associated with nonclinical development and formulation.
In addition, Navitor has granted Supernus an exclusive, worldwide (excluding Greater China) option to license or acquire NV-5138 prior to initiation of a Phase III clinical program. In exchange for the option to license or acquire NV-5138, Navitor will receive an upfront payment of $25 million, composed of a $10 million option fee and a $15 million equity investment. The equity investment represents an approximately 13% ownership in Navitor. Total payments, exclusive of royalty payments on net sales of NV-5138 and development costs under the agreement, have the potential to reach $410 million to $475 million, which includes the upfront payment, an additional license or acquisition fee depending on whether Supernus ultimately licenses or acquires NV-5138, and subsequent clinical, regulatory and sales milestone payments.
Supernus also will have the first right of refusal for any compound with a similar mechanism of action on mTORC1 as NV-5138 in the central nervous system.
SPN-604 – Novel treatment of bipolar disorder

The Company has reprioritized its research and development (R&D) resources following recent expansion of the product pipeline through mid to late-stage development product candidates. These product candidates include SPN-820 from the Navitor partnership and Apomorphine Infusion Pump from the US WorldMeds transaction. As a result, and given other factors including the estimated timing of a potential launch of SPN-604 and the required investment, the Company is terminating development of SPN-604 for the treatment of bipolar disorder.
Sales and marketing infrastructure

The acquisition of the CNS product portfolio from US WorldMeds includes a sales force of approximately 46 sales representatives that focuses on serving movement disorder specialists in the U.S.
The Company continues to plan on adding salesforce personnel toward the end of 2020 in anticipation of the launch of SPN-812.
"The two business development transactions that we announced over the last couple of weeks strengthen our product portfolio and late-stage pipeline, diversify our revenue base, enhance our long term growth, and strengthen our leadership position in CNS," said Jack Khattar, President and CEO of Supernus. "In addition, they expand our commercial and R&D platforms into the biologics, orphan disease and specialty pharmacy areas."

Operating Expenses

R&D expenses in the first quarter of 2020 were $18.9 million, compared to $15.4 million in the same quarter last year. This increase was primarily driven by enrollment in the SPN-812 Phase III program for adults, initiated in late 2019.

SG&A expenses in the first quarter of 2020 were $42.9 million, compared to $41.0 million in the same quarter last year. This increase was primarily driven by pre-launch activities associated with SPN-812, partially offset by a decrease in marketing expenses for commercial products and a decrease in employee-related expenses.

Operating Earnings and Earnings Per Share

Operating earnings in the first quarter of 2020 were $29.0 million, compared to $25.4 million in the first quarter of 2019. The increase of $3.6 million was primarily due to increased revenue from our two commercial products.

Net earnings (GAAP) in the first quarter of 2020 were $21.5 million, or $0.40 per diluted share, an increase of 18% on a diluted share amount, as compared to $18.3 million, or $0.34 per diluted share, in the same period last year.

Weighted-average diluted common shares outstanding were approximately 53.6 million for the first quarter of 2020, as compared to approximately 54.0 million for the prior year period.

Balance Sheet Highlights

As of March 31, 2020, the Company had $935.6 million in cash, cash equivalents, marketable securities and long term marketable securities, compared to $938.8 million at December 31, 2019. This decrease was primarily attributable to unrealized losses on long term marketable securities resultant from market volatility in the first quarter of 2020.

Financial Guidance

Given the uncertainty caused by the COVID-19 pandemic, the anticipated second quarter acquisition of the CNS portfolio from US WorldMeds and the impact of the partnership with Navitor Pharmaceuticals, the Company is suspending its previously issued full year 2020 financial guidance. The Company expects to update and reinstate full year 2020 guidance no later than the announcement of second quarter 2020 financial results in August.

Conference Call Details

The Company will hold a conference call hosted by Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Senior Vice President and Chief Financial Officer, to discuss these results at 9:00 a.m. Eastern Time, on Wednesday, May 6, 2020.

Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers

On May 5, 2020 Bayer reported the launch of Test4TRK program in collaboration with NeoGenomics, Inc. to offer genomic cancer testing for NTRK gene fusions at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) (Press release, Bayer, MAY 5, 2020, View Source [SID1234557054]). NTRK gene fusions, which have been shown to drive tumor growth, are more commonly found in patients with MSI-H mCRC and RAI-R DTC and may play a role in disease management.1-3 Bayer will cover the full cost of the test regardless of the results, treatment decision and patient’s insurance coverage. All eligible patients who enroll and opt-in to the program will receive an RNA-based next-generation sequencing (NGS) test, NTRK NGS Fusion Profile. Patients with an adequate tissue sample will also receive a Pan-Tropomyosin receptor kinase (Pan-TRK) Immunohistochemistry (IHC) test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Healthcare professionals and patients can visit www.Test4TRK.com to learn more and download the test request form or call Bayer Medical Communications at +1-888-84BAYER (+1-888-842-2937) for questions on NTRK gene fusions and TRK fusion cancer.

"The results of a genomic cancer test may be a deciding factor in treatment selection, especially for patients with differentiated thyroid cancer who have limited options," said Marcia S. Brose, M.D., Ph.D., Director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor in Otorhinolaryngology: Head and Neck Surgery at Penn’s Perelman School of Medicine, who collaborated on the development of the testing platform. "If we implement comprehensive genomic testing early upon diagnosis to uncover NTRK gene fusions, we may have a deeper understanding of patients’ tumors in aiding treatment decisions."

Genomic cancer testing helps detect changes in a tumor’s DNA, called genomic alterations, that can determine how the cancer behaves and why it grows or spreads.4 30-49 percent of patients who undergo genomic cancer testing may have actionable genomic alterations, meaning the alterations can be matched to treatments that have been approved or are in clinical trials.5,6

"After receiving a cancer diagnosis, patients and their loved ones critically need information that can help guide the course of their treatment journey," said Anjee Davis, president of Fight Colorectal Cancer (Fight CRC). "The Test4TRK program aligns with our commitment to empowering patients with educational resources. Colorectal cancer patients need to be armed with biomarker testing because their biomarkers can have an impact on treatment decisions, especially MSI-H. This can inform treatment plans and reduce financial barriers that could prevent some patients from receiving personalized care."

Bayer has developed this program in collaboration with patient organizations Thyroid Cancer Survivors’ Association, Inc. (ThyCa) and Fight CRC as well as Marcia S. Brose, MD, PhD of the University of Pennsylvania. Dr. Brose serves in an advisory role for Bayer and receives honoraria and funding for research support.

The Test4TRK program provides testing for an NTRK gene fusion, which occurs when an NTRK gene joins together, or fuses, with a different, unrelated gene. The NTRK gene fusion creates certain proteins (TRK fusion proteins) that can cause cancer cells to multiply and form a tumor.1 Cancers with NTRK gene fusions can occur in tumors that originate in different sites in the body in varying frequencies and are called TRK fusion cancers.7

"It is critical cancer patients have access to genomic testing for NTRK gene fusions to inform treatment decisions," said Joseph Germino, M.D., Vice President of Medical Affairs, Oncology at Bayer. "Bayer is providing the Test4TRK program as part of our continued efforts to empower the community and help increase the accuracy of cancer diagnoses to improve patient outcomes."

About the Test4TRK Program
Test4TRK is a Bayer-sponsored program offering laboratory testing for NTRK gene fusions (histology and molecular subject to tissue availability) at no cost to eligible patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). The test results provide information on whether the tumor harbors an NTRK gene fusion to aid in the treatment decision. Bayer will cover the full cost of the test regardless of the test results, treatment decision and patient’s insurance coverage for up to 500 patients in the U.S. Bayer will not cover the associated costs of extracting a viable tumor specimen. For more information, visit www.Test4TRK.com.

About Genomic Cancer Testing
It is important for patients diagnosed with cancer to discuss genomic cancer testing with their healthcare provider (HCP). Genomic cancer testing can identify DNA alterations, or changes, within cancer cells that determine how a tumor behaves or why it grows.4 Genomic cancer testing may help HCPs match patients to approved or investigational therapies based on the specific alteration identified.

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.